Title:
がん治療のためのＥＧＦＲ−ＳＧＬＴ１相互作用の標的化
Document Type and Number:
Japanese Patent JP6309080
Kind Code:
B2
Abstract:
A compound can destabilize an epidermal growth factor receptor (EGFR) protein and a sodium/glucose co-transporter 1 (SGLT 1) protein. In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer.
More Like This:
| WO/2009/018477 | METHODS OF INHIBITING CALCINEURIN WITH APOE ANALOGS |
| WO/2009/026529 | COMPOSITIONS AND METHODS USING VARIANT TAT PROTEINS |
| WO/2021/244623 | FERRITIN-ACE-2 SHORT PEPTIDE NANODRUG |
Inventors:
Wahua, Zan
Application Number:
JP2016513088A
Publication Date:
April 18, 2018
Filing Date:
May 08, 2014
Export Citation:
Assignee:
The University of Houston System
International Classes:
A61K38/10; A61K31/422; A61K31/4706; A61K31/4709; A61K31/506; A61K31/517; A61K31/5377; A61P35/00; A61P43/00; C07K7/08
Foreign References:
| US20130034558 |
Other References:
Dittmann K. et al.,EGFR cooperates with glucose transporter SGLT1 to enable chromatin remodeling in response to ionizing radiation,Radiotherapy and Oncology [online],ELSEVIER,2013年 4月17日,Vol.107, No.2,p.247-251,URL,http://dx.doi.org/10.1016/j.radonc.2013.03.016
Cancer Cell,2008年,Vol.13,p.385-393
Cancer Cell,2008年,Vol.13,p.385-393
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Natsuki Morishita